2023年1月5日

C2i Genomics将与阿斯利康(AstraZeneca)合作，探索C2i微小残留疾病(MRD)测试用于临床研究和药物开发。纽约- WEBWIRE - 2023年1月5日星期四，C2i Genomics的首席执行官兼联合创始人Asaf Zviran说:“这次合作通过提供超敏感和准确的癌症检测和多种实体癌症的监测，产生了有希望的结果。”癌症情报公司C2i Genomics今天宣布与全球科学领先的生物制药公司阿斯利康(LSE/STO/Nasdaq: AZN)扩大合作。两家公司合作评估实体癌症全基因组最小残留疾病(MRD)检测的潜力，目标是加强肿瘤治疗，支持临床试验招募和监测。C2i基因组公司已经完成了阿斯利康公司针对以色列初创企业的BeyondBio创新中心项目。使用人工生成的样本来复制预期在肿瘤中发现的不同水平的循环肿瘤DNA (ctDNA)，这项合作提供了早期证据，表明C2i测定法可以敏感地检测ctDNA(低至0.002%的等位基因频率)。在此基础上，阿斯利康将利用其内部测序能力和专业知识，进一步评估和验证C2i Genomics平台对患者来源样本的评估和验证。随着最近更便宜、更经济、更容易获得的全基因组测序(WGS)技术的发展，该行业正在继续改变癌症检测的方式。随着全基因组测序价格的下降，全球云基础设施容量和吞吐量的增加，以及机器学习和信号处理技术的综合发展，C2i基因组公司处于拐点的前沿，这将深刻改变癌症治疗监测和临床决策。从血浆中无创检测循环肿瘤DNA (ctDNA)已被证明对微小残留疾病(MRD)的检测、耐药性的出现和治疗反应的预测具有临床价值。 New MRD technologies aim to provide greater cancer detection sensitivity by expanding methods beyond small, personalized panels. C2i Genomics’ MRD technology applies whole-genome sequencing and artificial intelligence to a small blood sample to provide ultra-sensitive cancer detection. This technology aims to eliminate the need to develop a patient-specific assay, enabling high-performance, personalized monitoring and rapid turnaround across multiple solid cancers with reduced operational complexity. “This collaboration has generated promising results by providing ultra-sensitive and accurate cancer detection and monitoring across multiple solid cancers,” said Asaf Zviran, CEO and co-founder of C2i Genomics. “We’re looking forward to our continued collaboration with AstraZeneca to see where the power of our technologies can support the development of more effective cancer treatments for the patients that urgently need it.” C2i has expanded its SaaS solution across the globe, utilizing a cloud-based platform to perform cancer tumor burden monitoring. The collaboration with AstraZeneca comes after a period of successful partnerships and momentum, most recently with Karkinos Healthcare in India, OncoDNA across the EU, into China with NuProbe Global and an expansion in the greater US with Premier Inc. For companies interested in deploying C2i Genomics, please visit www.c2i-genomics.com . About C2i Genomics: Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. The company has raised over $112 million from leading institutional investors including Casdin Capital, NFX, Silver Lake, Duquesne Family Office, Section 32 and iGlobe Partners. For more information, please visit www.c2i-genomics.com . C2i was named to the 2021 CB Insights Digital 150 list and awarded the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by Frost & Sullivan. ( Press Release Image: https://photos.webwire.com/prmedia/42381/298865/298865-1.jpg )